By employing network pharmacology and molecular docking approaches, we aim to investigate the interactions between the bioactive constituents present in Zanthoxylum nitidum and the specific targets within the human body, with the ultimate goal of modulating the pathological mechanisms associated with Parkinson's Disease (PD). Relevant chemical components of Zanthoxylum nitidum were searched in TCSMP, CNKI, and Wanfang databases to obtain effective active components and predicted target genes. The component-gene target network was constructed using Cytoscape 3.7.2 software. Major targets of PD were obtained from the GEO database and compared with core gene targets of Zanthoxylum nitidum using a Venn diagram. Protein-protein interaction (PPI) network analysis was conducted on the intersection targets, and functional enrichment analysis was performed based on Gene Ontology (GO). Kyoto Encyclopedia of Genes and Genomes (KEGG) resources were used for enrichment studies on biological pathways to predict biological processes and pathways. The "drug-target-pathway" network was constructed using Cytoscape 3.7.2 software, and molecular docking was performed on core components and key targets using AutoDock vina software. A total of 38 compounds related to Zanthoxylum nitidum, 672 component targets, and 86 common targets between Zanthoxylum nitidum and PD were obtained. Network analysis revealed that the core active components of Zanthoxylum nitidum for treating PD are ethyl ferulate, dihydrochelerythrine, diosmetin, apigenin, and nitidine chloride. Core targets include AKT1, GAPDH, BCL2, EGFR, STAT3, and CASP3. GO and KEGG analyses showed that the pathways of Zanthoxylum nitidum in treating PD are mainly enriched in PI3K-Akt signaling pathway, Ras signaling pathway, and apoptosis signaling pathway. Its functions mainly include protein tyrosine kinase activity, transmembrane receptor protein kinase activity, and protein phosphatase binding. Molecular docking was performed between the top five key components of Zanthoxylum nitidum and six core genes screened by PPI. The chemical components in Zanthoxylum nitidum act on multiple pathways and targets to exert therapeutic effects on PD.

Shuya Gao, Shunli Liu, Jianjun Huang. Mechanism exploration of Zanthoxyli Radix in Parkinson's disease treatment via network pharmacology and molecular docking. Frontiers in Medical Science Research(2025), Vol. 7, Issue 2: 103-111. https://doi.org/10.25236/FMSR.2025.070215.

[1] CURRIM F, SINGH J, SHINDE A, et al. Exosome Release Is Modulated by the Mitochondrial-Lysosomal Crosstalk in Parkinson's Disease Stress Conditions [J]. Mol Neurobiol, 2021, 58(4).

[2] PéREZ DE LA CRUZ S. Effectiveness of aquatic therapy for the control of pain and increased functionality in people with Parkinson's disease: a randomized clinical trial [J]. Eur J Phys Rehabil Med, 2017, 53(6).

[3] CHAN Y T, WANG N, FENG Y. The toxicology and detoxification of Aconitum: traditional and modern views [J]. Chin Med, 2021, 16(1).

[4] LIANG M, ZHANG W, HU J, et al. Simultaneous analysis of alkaloids from Zanthoxylum nitidum by high performance liquid chromatography-diode array detector-electrospray tandem mass spectrometry [J]. J Pharm Biomed Anal, 2006, 42(2).

[5] MIRZAYEVA T, ČOPíKOVá J, KVASNIČKA F, et al. Screening of the Chemical Composition and Identification of Hyaluronic Acid in Food Supplements by Fractionation and Fourier-Transform Infrared Spectroscopy [J]. Polymers (Basel), 2021, 13(22).

[6] LO S F, MULABAGAL V, CHEN C L, et al. Bioguided fractionation and isolation of free radical scavenging components from in vitro propagated chinese medicinal plants Dendrobium tosaense Makino and Dendrobium moniliforme SW [J]. J Agric Food Chem, 2004, 52(23).

[7] YANG ZHONGDUO Z D, REN JIN. Skimmianine,a furoquinoline alkaloid from Emphasis Zanthoxylum nitidum/Emphasis as a potential acetylcholinesterase inhibitor[J]. J Med Chem res, 2012,21(6):722-725.

[8] BAO Y, GAO Y, CUI X. Effect of Shufeng Jiedu capsules as a broad-spectrum antibacterial [J]. Biosci Trends, 2016, 10(1).

[9] SCHMIDT D R, PATEL R, KIRSCH D G, et al. Metabolomics in cancer research and emerging applications in clinical oncology [J]. CA Cancer J Clin, 2021, 71(4).

[10] JAVED H, NAGOOR MEERAN M F, AZIMULLAH S, et al. Plant Extracts and Phytochemicals Targeting α-Synuclein Aggregation in Parkinson's Disease Models [J]. Front Pharmacol, 2018, 9.

[11] LIU Y P, GUO J M, WANG X P, et al. Geranylated carbazole alkaloids with potential neuroprotective activities from the stems and leaves of Clausena lansium [J]. Bioorg Chem, 2019, 92.

[12] NOGALES C, MAMDOUH Z M, LIST M, et al. Network pharmacology: curing causal mechanisms instead of treating symptoms [J]. Trends Pharmacol Sci, 2022, 43(2).

[13] LI S, ZHANG B. Traditional Chinese medicine network pharmacology: theory, methodology and application [J]. Chin J Nat Med, 2013, 11(2).

[14] DASHTI H, WEDELL J R, WESTLER W M, et al. Automated evaluation of consistency within the PubChem Compound database [J]. Sci Data, 2019, 6.

[15] DAINA A, MICHIELIN O, ZOETE V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules [J]. Sci Rep, 2017, 7.

[16] SHANNON P, MARKIEL A, OZIER O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks [J]. Genome Res, 2003, 13(11).

[17] YANG L, XU H, CHEN Y, et al. Melatonin: Multi-Target Mechanism Against Diminished Ovarian Reserve Based on Network Pharmacology [J]. Front Endocrinol (Lausanne), 2021, 12.

[18] TOULORGE D, SCHAPIRA A H, HAJJ R. Molecular changes in the postmortem parkinsonian brain [J]. J Neurochem, 2016, 139 Suppl 1.

[19] KAUR K, GILL J S, BANSAL P K, et al. Neuroinflammation - A major cause for striatal dopaminergic degeneration in Parkinson's disease [J]. J Neurol Sci, 2017, 381.

[20] ULANOWSKA M, OLAS B. Biological Properties and Prospects for the Application of Eugenol-A Review [J]. Int J Mol Sci, 2021, 22(7).

[21] WU Y X, WANG Y Y, GAO Z Q, et al. Ethyl ferulate protects against lipopolysaccharide-induced acute lung injury by activating AMPK/Nrf2 signaling pathway [J]. Acta Pharmacol Sin, 2021, 42(12).

[22] SCAPAGNINI G, BUTTERFIELD D A, COLOMBRITA C, et al. Ethyl ferulate, a lipophilic polyphenol, induces HO-1 and protects rat neurons against oxidative stress [J]. Antioxid Redox Signal, 2004, 6(5).

[23] SULTANA R, RAVAGNA A, MOHMMAD-ABDUL H, et al. Ferulic acid ethyl ester protects neurons against amyloid beta- peptide(1-42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity [J]. J Neurochem, 2005, 92(4).

[24] XIAO Y, SHAO K, ZHOU J, et al. Structure-based engineering of substrate specificity for pinoresinol-lariciresinol reductases [J]. Nat Commun, 2021, 12(1).

[25] OSHIMA T, ITO M. Sedative effects of l-menthol, d-camphor, phenylethyl alcohol, and geraniol [J]. J Nat Med, 2021, 75(2).

[26] CHANGKEB V, NOBSATHIAN S, LE GOFF G, et al. Insecticidal efficacy and possibility of Combretum trifoliatum Vent. (Myrtales: Combretaceae) extracts in controlling Spodoptera frugiperda (J.E. Smith) (Lepidoptera: Noctuidae) [J]. Pest Manag Sci, 2023, 79(12).

[27] DESHAIES R J, JOAZEIRO C A. RING domain E3 ubiquitin ligases [J]. Annu Rev Biochem, 2009, 78.

[28] CHUANG D M, HOUGH C, SENATOROV V V. Glyceraldehyde-3-phosphate dehydrogenase, apoptosis, and neurodegenerative diseases [J]. Annu Rev Pharmacol Toxicol, 2005, 45.

[29] MOON H E, YOON S H, HUR Y S, et al. Mitochondrial dysfunction of immortalized human adipose tissue-derived mesenchymal stromal cells from patients with Parkinson's disease [J]. Exp Neurobiol, 2013, 22(4).

[30] LI L, NADANACIVA S, BERGER Z, et al. Human A53T α-synuclein causes reversible deficits in mitochondrial function and dynamics in primary mouse cortical neurons [J]. PLoS One, 2013, 8(12).

[31] TARZE A, DENIAUD A, LE BRAS M, et al. GAPDH, a novel regulator of the pro-apoptotic mitochondrial membrane permeabilization [J]. Oncogene, 2007, 26(18).

[32] XIA M L, XIE X H, DING J H, et al. Astragaloside IV inhibits astrocyte senescence: implication in Parkinson's disease [J]. J Neuroinflammation, 2020, 17(1).

[33] SINGH R, LETAI A, SAROSIEK K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins [J]. Nat Rev Mol Cell Biol, 2019, 20(3).

[34] LEMASTERS J J. Dying a thousand deaths: redundant pathways from different organelles to apoptosis and necrosis [J]. Gastroenterology, 2005, 129(1).

[35] YIN F, ZHOU H, FANG Y, et al. Astragaloside IV alleviates ischemia reperfusion-induced apoptosis by inhibiting the activation of key factors in death receptor pathway and mitochondrial pathway [J]. J Ethnopharmacol, 2020, 248.

[36] LU H Y, CHEN X Q, TANG W, et al. GRP78 silencing enhances hyperoxia-induced alveolar epithelial cell apoptosis via CHOP pathway [J]. Mol Med Rep, 2017, 16(2).

[37] MEHRA S, SAHAY S, MAJI S K. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis [J]. Biochim Biophys Acta Proteins Proteom, 2019, 1867(10).

[38] HUBBARD S R, TILL J H. Protein tyrosine kinase structure and function [J]. Annu Rev Biochem, 2000, 69.